65 stories found
Bloomberg reports that AstraZeneca, Sanofi, and Boehringer Ingelheim are investing in Owkin's AI platform to overcome bottlenecks in pharmaceutical research and rapidly generate drug candidates.
Decision allows manufacturers to begin shipping doses, but confusion remains about insurance coverage The US Food and Drug Administration approved updated Covid-19 vaccines on Thursday, allowing manufacturers to begin shipping doses to pharmacies and doctors’ offices across the country. The FDA approved Moderna, Novavax-Sanofi and Pfizer-BioNTech’s updated Covid vaccines, the companies said on Thursday, after an advisory panel recommended that the shots should target the dominant XFG vari...
Despite a recent setback with Amlitelimab, analysts suggest that the incident is unlikely to significantly impact Sanofi's multi-billion dollar pharmaceutical engine.
Investment firm Antipodes has divested its holdings in pharmaceutical company Sanofi, citing a series of repeated setbacks in Sanofi's drug development pipeline as the reason for its exit.
Several companies, including MarketAxess, Jones Lang LaSalle, APi Group, and Regeneron, have reported robust second-quarter earnings that largely surpassed analyst estimates for both EPS and revenue. Regeneron notably saw a rise in its stock following strong performance driven by its high-dose Eylea.
Scribe, a company backed by pharmaceutical giants Eli Lilly and Sanofi, experienced a significant surge in its public market debut.
Sanofi announced that its drug Nexviazyme successfully met its primary endpoint in a clinical study for Pompe disease, marking a significant development for the treatment.
The United Nations has announced that over 50,000 people are missing in Venezuela following recent earthquakes, with the death toll exceeding 900. This comes as the EU continues various activities, including backing a Rett syndrome therapy and holding energy talks with Iraq.
The European Union has launched an antitrust investigation into French drugmaker Sanofi regarding its flu vaccine business. The probe will examine potential anti-competitive practices.
This collection of articles provides analysis on whether various companies, including TG Therapeutics, Trinity Industries, and Zillow Group, are good stocks to buy now. The reports offer insights into their investment potential.
Sanofi has stopped its phase 3 study of the drug riliprubart, intended for a rare nerve disease, citing concerns over its efficacy.
After five years at the helm of Merck, Belén Garijo is stepping down to take on the role of CEO at the French pharmaceutical company Sanofi. This move marks a significant career change for Garijo, who will be taking on a challenging new leadership position.
Sanofi announced upbeat sales figures, even as the company faces increasing pressure regarding its research and development efforts.
Multiple global companies across diverse sectors have announced their first-quarter financial results, with many reporting stronger-than-expected earnings and revenue. These firms often exceeded analyst estimates and provided positive outlooks for the upcoming quarter or full fiscal year.
The U.S. Food and Drug Administration has broadened the use of Sanofi's drug Tzield, allowing it to be administered to children as young as one year old to delay the onset of type 1 diabetes.
Sanofi announced that its drug lunsekimig successfully met primary and key secondary endpoints in its Phase 2 trials for both Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).
The European Union regulator has given its backing to Sanofi's injectable version of a blood cancer drug, specifically recommending approval for the subcutaneous version of Scarlisa (isatuximab).
Pharmaceutical giant Sanofi is reportedly selling its Medley unit to Brazilian company EMS for more than $500 million, marking a significant divestment.
European drug regulators on Friday endorsed a new and simpler treatment for sleeping sickness, in what could be a giant boost to efforts to eliminate the disease. A European Medicines Agency committee gave its nod to acoziborole, developed by Sanofi and DNDi. Speaking to France 24, Dr Luis Pizarro, executive director of DNDi, said the new pill could revolutionise treatment of the disease, which has killed hundreds of thousands across Africa.
Sanofi has announced the appointment of Manuela Buxo as the new head of its Specialty Care Global Business Unit.
Multiple biotech and pharmaceutical companies, including Legend Biotech, Corcept Therapeutics, and Ultragenyx, have released updates on their drug pipelines, clinical trial data, and regulatory interactions, impacting market outlook.
Boehringer Ingelheim has partnered with artificial intelligence firm Owkin to accelerate drug discovery efforts focused on cancer and immunology. The collaboration marks another major industry move as pharmaceutical companies increasingly integrate machine learning into early-stage research.
Trading below nine times earnings and offering a 5.4% dividend yield, pharmaceutical giant Sanofi recently secured a key FDA approval, drawing attention from value-focused portfolios seeking stable returns.
Novavax reported stronger-than-expected earnings, with its strategic partnership with Sanofi showing significant advancement.
Sanofi's MenQuadfi vaccine has received approval in the European Union for use in infants to protect against meningococcal disease.
Several companies, including Plexus, Preformed Line Products, Endeavour Silver, Cactus, Spok, Insperity, Arxis, CONMED, and Everest Group, reported their latest quarterly earnings, with most beating analyst expectations for EPS and revenue. Starbucks, however, saw a significant decline in international revenue, and Pilgrim's Pride missed on both EPS and revenue.
The European Parliament has passed a historic resolution recognizing the rapes of women in Cyprus during the 1974 Turkish invasion. This decision comes amidst other European Union discussions, including Serbia's stalled EU accession and Romania facing legal action over payment delays.
Financial analysts have adjusted their price targets and forecasts for several entities, with Bank of America raising its target for American Airlines and Deutsche Bank cutting its target for Sanofi. Additionally, a bank has significantly lowered its gold price forecast.
The European Commission is investigating French pharmaceutical giant Sanofi over suspicions of engaging in a 'misleading communication campaign' that may have hindered competition, potentially leading to a fine.
The European Commission has approved Sanofi's Cenrifki (tolebrutinib), marking the first drug in the European Union specifically approved to slow the progression of secondary progressive multiple sclerosis (SPMS) without relapses.
Donald Trump announced that a peace deal between the US and Iran would be signed on Sunday, a claim met with disagreement from Iran regarding the timing. The impending agreement sparked strong reactions, including criticism from Israeli Prime Minister Netanyahu who convened an emergency security council meeting.
Markus Isenmann, Sanofi's head of Specialty Care for Austria and Switzerland, discusses the pharmaceutical industry in Austria, bureaucratic hurdles, digital twins, and employee management.
Iran's foreign minister arrived in Pakistan, fueling speculation about potential direct talks with the U.S. President Trump stated he anticipates Iran will present an offer aimed at satisfying American demands.
Pharmaceutical company Sanofi reported first-quarter earnings that topped analyst estimates, primarily due to strong sales of its drug Dupixent, and reaffirmed its full-year outlook.
Sanofi and Regeneron's drug Dupixent has received approval, becoming the first biologic treatment available for children under 12 suffering from chronic spontaneous urticaria (CSU).
US-Iran negotiations are marked by President Trump's threats of military action if a deal isn't reached, while Iran sends mixed signals due to internal divisions. Regional states and international bodies express concerns, including for freedom of navigation in the Strait of Hormuz.
Sanofi has announced late-breaking phase 3 data for its drug amlitelimab, targeting atopic dermatitis, a significant development in the treatment of the skin condition.
Sanofi has announced that its drug Venglustat has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA).
From a garden-lined ‘arrival experience’ to studio-style meeting rooms, this office blurs the boundaries between work and home
Regeneron and Sanofi have announced that their drug Dupixent has received a label expansion, allowing it to be used for the treatment of allergic fungal rhinosinusitis.
Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions Reuters
Drugmaker Sanofi announced plans to expand its India Global Capability Center, aiming to increase its workforce to over 4,500 employees.
The U.S. Food and Drug Administration has granted approval for newly developed COVID-19 vaccines from Pfizer, Moderna, and Sanofi, expanding available options for public immunization efforts.
The Portuguese Competition Authority has given its approval for several acquisitions, including the purchase of the Labina group, FBO Motors Sports by FXRS, and Sanofi by Substipharm. The authority also withdrew its decision on the purchase of Mocoffee and approved the acquisition of RsKalgar.
Novavax surpassed earnings estimates as its strategic partnership with Sanofi continues to advance, signaling positive developments for the company.
Under CEO Belén Garijo, pharmaceutical giant Sanofi is actively pursuing significant innovation to catch up with competitors, facing high expectations in a competitive market.
European stocks saw advances on a busy day for earnings reports, with positive results from companies like Schneider Electric SE and Rolls-Royce Holdings Plc. These gains outweighed a slump in Sanofi SA shares.
Changes in Sanofi SA's (SNY) research and development strategy are underscoring its potential as one of the best dividend stocks for investors.
Bank of America analysts anticipate a positive investor reaction to an upcoming leadership update from pharmaceutical company Sanofi (SNY).
The European Commission has launched an investigation into whether French pharmaceutical giant Sanofi violated EU competition rules with its flu vaccination advertising campaign.
MacroGenics has received a $24.5 million payment from Sanofi following the approval of Tzield.
Dianthus shares fell after Sanofi announced it was halting a late-stage trial for a CIDP (chronic inflammatory demyelinating polyneuropathy) therapy due to efficacy concerns.
Emmanuel Frenehard, Sanofi's digital director, shares how the company is leveraging AI to accelerate drug development, aiming to reduce the process from ten to five years. He applies his experience from the entertainment sector to the pharmaceutical industry.
BNP Paribas has downgraded Sanofi, citing an unlikely near-term rerating for the pharmaceutical company.
Pharmaceutical company Sanofi has posted higher sales figures during a period of leadership transition, as reported by the Wall Street Journal.
Tesla reported first-quarter earnings that surpassed analyst expectations, leading to a surge in its stock price. The automaker attributed its strong performance to increased deliveries and a rebound in demand for electric vehicles, alongside a pivot towards AI and robotics.
Sanofi and Regeneron's drug Dupixent has received approval in the European Union for treating young children suffering from chronic urticaria, expanding its use for pediatric patients.
An analyst has initiated coverage of Sanofi (SNY) with an 'Outperform' rating, indicating a positive outlook for the pharmaceutical company's stock.
Huons has signed a distribution and co-promotion agreement with Sanofi Korea, effective April 1, marking its entry into the domestic vaccine market with five vaccines.
Brazilian pharmaceutical company EMS is reportedly looking for overseas acquisition opportunities following its recent purchase of a Sanofi unit.
Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 billion Reuters
Teva and Sanofi announced durable phase 2b efficacy results for their drug duvakitug, intended for the treatment of ulcerative colitis and Crohn's disease.